Figure 2
Figure 2. Col7 protein is expressed in the skin of treated Col7a1−/− animals. Representative images of footpad skin of wild-type control (first column), untreated RDEB (second column; dashed line indicates dermal-epidermal junction), and CD150+CD48− BM-treated RDEB (third column and fourth—magnified view—column) are shown. Isotype control (viewed in red fluorescence channel; top row); anti-col7 antibody (red, second row, tight linear band at the skin basement membrane zone in the wild type in the leftmost column, and positive col7a staining in the treated RDEB in the rightmost column); anti-GFP antibody (green, third row, GFP-positive cells are indicated with horizontal arrows); and merged images with blue DAPI nuclear stain (bottom row, col7 indicated with vertical arrows). Merged images demonstrate the colocalization of GFP+ donor cells and collagen type VII in the skin 10 weeks after CD150+CD48− BM infusion.

Col7 protein is expressed in the skin of treated Col7a1−/− animals. Representative images of footpad skin of wild-type control (first column), untreated RDEB (second column; dashed line indicates dermal-epidermal junction), and CD150+CD48 BM-treated RDEB (third column and fourth—magnified view—column) are shown. Isotype control (viewed in red fluorescence channel; top row); anti-col7 antibody (red, second row, tight linear band at the skin basement membrane zone in the wild type in the leftmost column, and positive col7a staining in the treated RDEB in the rightmost column); anti-GFP antibody (green, third row, GFP-positive cells are indicated with horizontal arrows); and merged images with blue DAPI nuclear stain (bottom row, col7 indicated with vertical arrows). Merged images demonstrate the colocalization of GFP+ donor cells and collagen type VII in the skin 10 weeks after CD150+CD48 BM infusion.

Close Modal

or Create an Account

Close Modal
Close Modal